These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 25013123)
1. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Suryani S; Carol H; Chonghaile TN; Frismantas V; Sarmah C; High L; Bornhauser B; Cowley MJ; Szymanska B; Evans K; Boehm I; Tonna E; Jones L; Manesh DM; Kurmasheva RT; Billups C; Kaplan W; Letai A; Bourquin JP; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2014 Sep; 20(17):4520-31. PubMed ID: 25013123 [TBL] [Abstract][Full Text] [Related]
2. Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL Budhraja A; Turnis ME; Churchman ML; Kothari A; Yang X; Xu H; Kaminska E; Panetta JC; Finkelstein D; Mullighan CG; Opferman JT Clin Cancer Res; 2017 Dec; 23(24):7558-7568. PubMed ID: 28974549 [No Abstract] [Full Text] [Related]
3. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611 [TBL] [Abstract][Full Text] [Related]
5. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826 [TBL] [Abstract][Full Text] [Related]
6. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
7. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015 [TBL] [Abstract][Full Text] [Related]
8. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384 [TBL] [Abstract][Full Text] [Related]
9. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
10. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911 [TBL] [Abstract][Full Text] [Related]
12. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245 [TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Lock R; Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu J; Smith MA Pediatr Blood Cancer; 2008 Jun; 50(6):1181-9. PubMed ID: 18085673 [TBL] [Abstract][Full Text] [Related]
14. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841 [TBL] [Abstract][Full Text] [Related]
15. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Hauck P; Chao BH; Litz J; Krystal GW Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561 [TBL] [Abstract][Full Text] [Related]
16. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics. Mattoo AR; Zhang J; Espinoza LA; Jessup JM Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882 [TBL] [Abstract][Full Text] [Related]
18. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704 [TBL] [Abstract][Full Text] [Related]
19. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162 [TBL] [Abstract][Full Text] [Related]
20. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]